89bio, Inc.
ETNBNASDAQHealthcare
$14.84
+$0.00(+0.00%)
Market Cap$2.2B
P/E Ratio—
52W High$15.06
52W Low$4.16
89bio, Inc. (ETNB) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ETNB · earnings · updated Jun 8, 2026
Latest Earnings
Q4 FY2025Report Date: Nov 6, 2025EPS Actual
-$1.39
Est. -$0.50 · -178.0%
Revenue
—
Fiscal Period
Q4 FY2025
FY ends December
Report Date
Nov 6, 2025
After Market Close
▼ Miss EPS
ETNB reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ▼ Q4 FY2025 | Nov 6, 2025 | -$0.50 | -$1.39 | -178.0% | — | — | — |
| ▼ Q3 FY2025 | Aug 7, 2025 | -$0.49 | -$0.71 | -44.9% | — | — | — |
| ▲ Q2 FY2025 | May 1, 2025 | -$0.50 | -$0.49 | +2.0% | — | — | — |
| ▼ Q1 FY2025 | Feb 27, 2025 | -$0.60 | -$1.02 | -70.0% | $0.00B | — | — |
| ▼ Q4 FY2024 | Nov 7, 2024 | -$0.64 | -$1.39 | -117.2% | — | $0.00B | — |
| ▲ Q3 FY2024 | Aug 5, 2024 | -$0.57 | -$0.48 | +15.8% | — | $0.00B | — |
| ▼ Q2 FY2024 | May 9, 2024 | -$0.46 | -$0.54 | -17.4% | — | — | — |
| ▼ Q1 FY2024 | Feb 29, 2024 | -$0.49 | -$0.50 | -2.0% | $0.00B | — | — |
Q4 FY2025
Nov 6, 2025Miss
EPS Actual
-$1.39
EPS Est.
-$0.50
EPS Surpr.
-178.0%
Revenue
—
Q3 FY2025
Aug 7, 2025Miss
EPS Actual
-$0.71
EPS Est.
-$0.49
EPS Surpr.
-44.9%
Revenue
—
Q2 FY2025
May 1, 2025Beat
EPS Actual
-$0.49
EPS Est.
-$0.50
EPS Surpr.
+2.0%
Revenue
—
Q1 FY2025
Feb 27, 2025Miss
EPS Actual
-$1.02
EPS Est.
-$0.60
EPS Surpr.
-70.0%
Revenue
$0.00B
Q4 FY2024
Nov 7, 2024Miss
EPS Actual
-$1.39
EPS Est.
-$0.64
EPS Surpr.
-117.2%
Revenue
—
Q3 FY2024
Aug 5, 2024Beat
EPS Actual
-$0.48
EPS Est.
-$0.57
EPS Surpr.
+15.8%
Revenue
—
Q2 FY2024
May 9, 2024Miss
EPS Actual
-$0.54
EPS Est.
-$0.46
EPS Surpr.
-17.4%
Revenue
—
Q1 FY2024
Feb 29, 2024Miss
EPS Actual
-$0.50
EPS Est.
-$0.49
EPS Surpr.
-2.0%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $-0.60 | $-0.60 | $-0.60 | 1 |
| Q3 FY2026 | $-0.57 | $-0.57 | $-0.57 | 1 |
| Q2 FY2026 | $-0.56 | $-0.56 | $-0.56 | 1 |
| Q1 FY2026 | $-0.55 | $-0.55 | $-0.55 | 1 |
| Q4 FY2025 | $-0.52 | $-0.52 | $-0.52 | 4 |
| Q3 FY2025 | $-0.51 | $-0.50 | $-0.49 | 5 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q4 FY2025 | Nov 6, 2025 | -178.0% | $14.84 | — | — |
| ▼ Q3 FY2025 | Aug 7, 2025 | -44.9% | $9.48 | $9.02 | -4.85% |
| ▲ Q2 FY2025 | May 1, 2025 | +2.0% | $8.02 | $8.13 | +1.37% |
| ▼ Q1 FY2025 | Feb 27, 2025 | -70.0% | $9.21 | $9.32 | +1.19% |
| ▼ Q4 FY2024 | Nov 7, 2024 | -117.2% | $10.17 | $9.96 | -2.06% |
| ▲ Q3 FY2024 | Aug 5, 2024 | +15.8% | $8.91 | $8.39 | -5.84% |
| ▼ Q2 FY2024 | May 9, 2024 | -17.4% | $9.03 | $9.11 | +0.89% |
| ▼ Q1 FY2024 | Feb 29, 2024 | -2.0% | $11.76 | $11.47 | -2.47% |
Q4 FY2025—
Report Date
Nov 6, 2025
EPS Beat/Miss
-178.0%
Price Before
$14.84
Price After
—
Q3 FY2025-4.85%
Report Date
Aug 7, 2025
EPS Beat/Miss
-44.9%
Price Before
$9.48
Price After
$9.02
Q2 FY2025+1.37%
Report Date
May 1, 2025
EPS Beat/Miss
+2.0%
Price Before
$8.02
Price After
$8.13
Q1 FY2025+1.19%
Report Date
Feb 27, 2025
EPS Beat/Miss
-70.0%
Price Before
$9.21
Price After
$9.32
Q4 FY2024-2.06%
Report Date
Nov 7, 2024
EPS Beat/Miss
-117.2%
Price Before
$10.17
Price After
$9.96
Q3 FY2024-5.84%
Report Date
Aug 5, 2024
EPS Beat/Miss
+15.8%
Price Before
$8.91
Price After
$8.39
Q2 FY2024+0.89%
Report Date
May 9, 2024
EPS Beat/Miss
-17.4%
Price Before
$9.03
Price After
$9.11
Q1 FY2024-2.47%
Report Date
Feb 29, 2024
EPS Beat/Miss
-2.0%
Price Before
$11.76
Price After
$11.47
Avg Beat Reaction-2.23%
Avg Miss Reaction-1.46%
Beat Rate2 / 8 quarters
Largest Move-5.84% (Q3 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ETNB ends December
89bio, Inc. (ETNB) most recently reported earnings on November 6, 2025 for Q4 FY2025, posting EPS of $-1.39 — missing the analyst consensus of $-0.50 by -178.0%. The next ETNB earnings date is expected around September 1, 2026.
Each quarter, investors track ETNB earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ETNB revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ETNB's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ETNB earnings · 5 questions89bio, Inc.'s next earnings report is expected around September 1, 2026. ETNB typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ETNB historically reports after market close (AMC).
ETNB earnings datewhen is ETNB earningsETNB next earnings datewhen does ETNB report earningsETNB earnings calendar
▸ Source: FMP · 89bio, Inc. SEC filings · US GAAP · 89bio, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026